Key Takeaways:
Zhonghui Biotech (中辉生物科技, 02627.HK) announced its auditor, Deloitte Touche Tohmatsu, resigned effective April 13, prolonging a trading suspension that began on April 1.
"Deloitte Touche Tohmatsu resigned as its auditor with immediate effect... as certain audit procedures in relation to certain fund investments and certain consultancy payments... have not yet been completed," the company said in a filing to the Hong Kong Stock Exchange.
The outstanding audit items are part of an ongoing internal inquiry initiated by the board's audit committee, which remain "subject to further review." Trading in the company's H shares has been suspended since April 1 and will remain so until further notice. The company has not yet completed its 2025 audit or published its annual results.
The abrupt resignation of a Big Four auditor severely damages investor confidence and raises serious questions about Zhonghui Biotech's financial transparency and internal controls. The company will likely face a sharp stock decline if trading resumes and could be subject to regulatory penalties. Finding a new reputable auditor willing to take on the engagement may prove difficult, potentially extending the trading suspension and leaving investors in prolonged uncertainty.
This article is for informational purposes only and does not constitute investment advice.
